Innovation Theaters Schedule

Thursday, April 3

Morning Break 10:15-11:00 a.m. Theater 1
Eosinophils in COPD: Identifying Your High-risk Patients
Sponsored by: GSK
Emerging evidence in COPD suggests that type 2 (T2) inflammation characterized by blood eosinophil count (BEC) may be present in up to 40% of patients. Hear from a pulmonologist on how T2 inflammation puts patients with COPD at increased risk and how the BEC can help identify these patients.
Antonio Anzueto, MD
San Antonio, TX

Morning Break 10:15-11:00 a.m. Theater 2
PrEP Today. Data Discussions on an HIV-1 PrEP Option
Sponsored by: ViiV Healthcare
Learning Objectives:

• Uncover the unmet needs of people taking daily oral PrEP
• Learn about the clinical trial and patient choice data
• Hear from a patient ambassador about their PrEP journey
• Discuss the patient and clinical considerations for this PrEP option

Morning Break 10:15-11:00 a.m. Theater 3
Shifting the Paradigm in Cancer Screening: The Promise, Potential, and Pressing Questions of Multi-Cancer Early Detection (MCED) Testing
Sponsored by: Exact Sciences
This presentation will explore the potential of multi-cancer early detection (MCED) tests, a technology poised to transform cancer care by screening for multiple cancers. It will examine the technology's promise to potentially improve outcomes while addressing questions related to mortality benefits, overdiagnosis, and false positives.
Michelle Beidelschies, PhD
Cleveland, OH

Lunch 12:30-1:15 p.m. Theater 1
Learn how to Dramatically Lower Your Established CVD Patients' LDL-C and Reduce Their Risk of MI, Stroke, and Coronary Revascularization
Sponsored by: Amgen
In this presentation, we will discuss the recommendation from the ACC Expert Consensus Decision Pathway around a lower LDL-C threshold for patients with ASCVD at very high risk for CV event.
John B. Calado, DO, FACOI
Troy, MI

Lunch 12:30-1:15 p.m. Theater 2
Unlocking the Potential of FreeStyle Libre Systems to Empower Patients and Providers
Sponsored by: Abbott
Join us to explore the benefits of managing patients with diabetes with continuous glucose monitoring technology. Learn about the impact that FreeStyle Libre systems has made on clinical outcomes by driving patient engagement and fostering behavior change. Enhance your practice with cutting-edge CGM insights. 
Lowell Schmeltz, MD
Farmington Hills, MI

Lunch 12:30-1:15 p.m. Theater 3
Understanding Adult Immunization for Herpes Zoster and RSV
Sponsored by: GSK
Explore adult immunization rates, risk factors, and CDC recommendations for RSV and Shingles. Discover insights into identifying at-risk patients, coadministration with other vaccines, and disease incidence. Discuss clinical studies of Arexvy and Shingrix, and key considerations for RSV and Herpes Zoster vaccinations in this vulnerable population.
Robert Feldman, MD
Laguna Hills, CA

Afternoon Break 3:45-4:30 p.m. Theater 2
HIV Prevention as Primary Care
Sponsored by: Gilead Sciences, Inc.
Increasing PrEP uptake is an important part of helping to end the HIV epidemic. This program will discuss how PCPs can play a pivotal role in PrEP uptake and will explain ways to implement PrEP in primary care practices. Select details of a pivotal trial for a PrEP medication option are also examined.

Friday, April 4

Morning Break 10:15-11:00 a.m. Theater 1
Detect and Help Prevent CRC with the Cologuard Plus™ test 
Sponsored by: Exact Sciences
Join us to learn how to integrate Cologuard into your screening protocol for your 45+ average risk patients for CRC. During this data-driven session, we'll present new information about the Cologuard Plus test and share how you can integrate a CRC screening approach to help improve adherence and outcomes.
Bradley Anderson, MD, GI
Columbus, MO
Keith Winfrey, MD, MPH
New Orleans, LA

Morning Break 10:15-11:00 a.m. Theater 2
Learn About a Trusted and Proven Treatment with Years of Experience in Patients with Uncontrolled Gout
Sponsored by: Amgen
This program will examine 1) uncontrolled gout as chronic, systemic, and highly comorbid with a range of diseases, 2) an effective treatment option with a proven safety profile and over 13 years of real-world experience, and 3) best practices for referring patients early in the course of disease.
Scott Neville, DPM, FACFAS
Mooresville, IN

Morning Break 10:15-11:00 a.m. Theater 3
Sponsored by: Pfizer

Lunch 12:30-1:15 p.m. Theater 1
Streamlining Diabetes Management: Unlocking the Potential of CGM in Your Practice
Sponsored by: Dexcom
Join Dexcom for an engaging session on Continuous Glucose Monitoring (CGM) tailored for primary care. Discover practical tips, clinical evidence, and real-world workflow examples to enhance patient engagement and streamline clinic processes with Dexcom Technology.
Thomas Martens, MD, FACP
Minneapolis, MN
Gregg Simonson, PhD
Minneapolis, MN

Lunch 12:30-1:15 p.m. Theater 2
Evidence-Based Recommendations for the Treatment of COVID-19
Sponsored by: Gilead Sciences, Inc.
Today’s treatment of COVID-19 – An expert’s perspective.
Ankur Segon, MD, MPH
UT Health San Antonio

Lunch 12:30-1:15 p.m. Theater 3
DISCOVER THE IMPACT OF GEMTESA: A Selective β3-Adrenergic Agonist for Effective OAB Treatment
Sponsored by: Sumitomo Pharma America, Inc.
In this program, the faculty will discuss unmet needs in OAB management and present clinical data on a β3-adrenergic receptor agonist for the treatment of OAB. Illustrative patient case studies will be featured throughout the presentation. This non-CME program is sponsored by Sumitomo Pharma America, Inc.
Larry Neuman, MD
New York, NY

Afternoon Break 3:45-4:30 p.m. Theater 2
Discover Shield | Revolutionary Blood Test for Colorectal Cancer Screening
Sponsored by: Guardant Health
Please join us to learn about Shield - the first and only FDA approved blood test with medicare coverage for colorectal cancer screening. We will review the following:

• CRC background/screening challenges
• Shield’s performance published in NEJM
• How Shield can be implemented into your practice to help increase adherence

Victoria Raymond, MS
Palo Alto, CA